UA103558C2 - Sustained release tablet containing theobromine - Google Patents
Sustained release tablet containing theobromineInfo
- Publication number
- UA103558C2 UA103558C2 UAA201206606A UAA201206606A UA103558C2 UA 103558 C2 UA103558 C2 UA 103558C2 UA A201206606 A UAA201206606 A UA A201206606A UA A201206606 A UAA201206606 A UA A201206606A UA 103558 C2 UA103558 C2 UA 103558C2
- Authority
- UA
- Ukraine
- Prior art keywords
- sustained release
- theobromine
- tablet containing
- release layer
- release tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a sustained release tablet containing theobromine. More particularly, the present invention relates to a sustained release tablet containing theobromine, comprising a sustained release layer and an immediate release layer, wherein the sustained release layer consists of 40 to 60 wt % of theobromine as an active ingredient, and 14 to 19 wt % of a sustained release base consisting of polyethylene oxide and hydroxypropyl methylcellulose, and the immediate release layer consists of 10 to 30 wt % of theobromine as an active ingredient, and 0.5 to 2 wt % of a disintegrant consisting of one or more elements selected from among croscarmellose sodium, crospovidone and sodium starch glycolate. The sustained release table of the present invention effectively improves various types of cough symptoms by being taken just once per day.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090105137A KR101137467B1 (en) | 2009-11-02 | 2009-11-02 | Extended-release tablet containing theobromine |
PCT/KR2010/005911 WO2011052884A2 (en) | 2009-11-02 | 2010-09-01 | Sustained release tablet containing theobromine |
Publications (1)
Publication Number | Publication Date |
---|---|
UA103558C2 true UA103558C2 (en) | 2013-10-25 |
Family
ID=43922740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201206606A UA103558C2 (en) | 2009-11-02 | 2010-09-01 | Sustained release tablet containing theobromine |
Country Status (7)
Country | Link |
---|---|
KR (1) | KR101137467B1 (en) |
CN (1) | CN102711740B (en) |
BR (1) | BR112012010325B8 (en) |
RU (1) | RU2506947C2 (en) |
TR (1) | TR201205029T1 (en) |
UA (1) | UA103558C2 (en) |
WO (1) | WO2011052884A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101220830B1 (en) * | 2010-08-18 | 2013-01-10 | 안국약품 주식회사 | Sustained-release granules of theobromine and its preparing method |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR040680A1 (en) * | 2002-07-25 | 2005-04-13 | Pharmacia Corp | COMPOSITION OF SUSTAINED RELEASE TABLETS |
DE10353196A1 (en) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Multilayer dosage form with a matrix influencing the delivery of a modulatory substance |
KR20070017335A (en) * | 2004-03-22 | 2007-02-09 | 노파르티스 아게 | Oral matrix formulations comprising licarbazepine |
CN101111231A (en) * | 2005-03-29 | 2008-01-23 | 罗姆有限公司 | Multiparticulate pharmaceutical form comprising pellets with a matrix which influences the delivery of a modulatory substance |
KR100762847B1 (en) * | 2006-01-27 | 2007-10-04 | 씨제이 주식회사 | Multiple unit type sustained release oral formulation and process for the preparation thereof |
-
2009
- 2009-11-02 KR KR1020090105137A patent/KR101137467B1/en active IP Right Grant
-
2010
- 2010-09-01 RU RU2012119070/15A patent/RU2506947C2/en active
- 2010-09-01 UA UAA201206606A patent/UA103558C2/en unknown
- 2010-09-01 WO PCT/KR2010/005911 patent/WO2011052884A2/en active Application Filing
- 2010-09-01 CN CN201080051266.9A patent/CN102711740B/en not_active Expired - Fee Related
- 2010-09-01 BR BR112012010325A patent/BR112012010325B8/en not_active IP Right Cessation
- 2010-09-01 TR TR2012/05029T patent/TR201205029T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20110048367A (en) | 2011-05-11 |
BR112012010325B1 (en) | 2021-01-26 |
WO2011052884A3 (en) | 2011-07-14 |
RU2012119070A (en) | 2013-12-10 |
CN102711740B (en) | 2014-02-12 |
BR112012010325B8 (en) | 2021-05-25 |
CN102711740A (en) | 2012-10-03 |
TR201205029T1 (en) | 2012-09-21 |
BR112012010325A2 (en) | 2016-03-29 |
WO2011052884A2 (en) | 2011-05-05 |
KR101137467B1 (en) | 2012-04-20 |
RU2506947C2 (en) | 2014-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA017091B9 (en) | Fumarate salt of (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol | |
MX2012007375A (en) | 3-keto-n-propargyl-1-aminoindan. | |
IN2012DN01378A (en) | ||
MX2009004746A (en) | 1,2,4-triazole derivatives as sigma receptor inhibitors. | |
ZA200809864B (en) | Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic | |
UA89394C2 (en) | Orally disintegrating composition of olanzapine or donepezil | |
TNSN08191A1 (en) | Kinase inhibitors | |
MX2013014788A (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]am ino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids. | |
IL193357A0 (en) | Metoprolol succinate e.r. tablets and methods for their preparation | |
EA201201263A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE | |
MX2009006567A (en) | Pyrimidinyl pyrazoles as insecticides and parasiticide active agents. | |
IN2012DN00954A (en) | ||
RU2008135718A (en) | COMPOSITIONS OF BISULPHATE CLOPIDOGEL | |
MY151005A (en) | Amide compounds as boosters of antivirals | |
TW200718698A (en) | Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof | |
MX2011010359A (en) | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbony l)-pyridin-2-yl]-benzamide. | |
TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
CY1109865T1 (en) | Valsartan Compositions | |
MY152685A (en) | Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments | |
UA103558C2 (en) | Sustained release tablet containing theobromine | |
WO2011064797A3 (en) | Controlled release pharmaceutical compositions of galantamine | |
MY152040A (en) | Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments | |
ATE438381T1 (en) | ZOLPIDEME TABLETS | |
WO2010018593A3 (en) | Gastric acid resistant benzimidazole multiple unit tablet composition | |
WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate |